Experimental approaches for the treatment of malignant gliomas

This publication has 416 references indexed in Scilit:

• Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
  Journal of Neuro-Oncology, 2009
• Phase I Trial Using Proteasome Inhibitor Bortezomib and Concurrent Temozolomide and Radiotherapy for Central Nervous System Malignancies
  International Journal of Radiation Oncology*Biology*Physics, 2009
• Phase 1 trial of temozolomide plus irinotecan plus O⁶-benzylguanine in adults with recurrent malignant glioma
  Cancer, 2009
• Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
  Cancer, 2009
• A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
  Journal of Neuro-Oncology, 2008
• Phase I Trial of Tipifarnib (R115777) Concurrent With Radiotherapy in Patients with Glioblastoma Multiforme
  International Journal of Radiation Oncology*Biology*Physics, 2007
• The 2007 WHO Classification of Tumours of the Central Nervous System
  Acta Neuropathologica, 2007
• HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity
  Current Biology, 2007
• AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
  Cancer Cell, 2007
• Thalidomide is an inhibitor of angiogenesis.
  Proceedings of the National Academy of Sciences, 1994